Summary: In this issue, Gainor and colleagues report on the immunogenicity of personalized neoantigen-encoding mRNA vaccines that elicit measurable polyfunctional CD8+ and CD4+ T-cell responses in patients whose tumors have been resected. Reactivity is substantiated to 20% to 30% of the predicted MHC-I and MHC-II epitopes in four patients with NSCLC postsurgically treated with the vaccine alone and in 12 patients with melanoma treated with their individualized vaccines plus pembrolizumab in the context of a phase 1 clinical trial (NCT03313778). See related article by Gainor et al., p. 2209

中文翻译：

---

个性化辅助 mRNA 癌症疫苗的免疫原性和疗效


摘要： 在本期中，Gainor 及其同事报告了个性化新抗原编码 mRNA 疫苗的免疫原性，这些疫苗在肿瘤切除的患者中引起可测量的多功能 CD8+ 和 CD4+ T 细胞反应。在 1 期临床试验 （NCT03313778） 的背景下，4 名术后单独接受疫苗治疗的 NSCLC 患者和 12 名接受个体化疫苗加帕博利珠单抗治疗的黑色素瘤患者，反应性证实为预测 MHC-I 和 MHC-II 表位的 20% 至 30%。参见 Gainor 等人的相关文章，第 2209 页